65/100 · Elevated
Manufactured by Sandoz Inc
Moderate Safety Concerns with Methylphenidate Hydrochloride
101,957 FDA adverse event reports analyzed
Last updated: 2026-05-12
METHYLPHENIDATE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sandoz Inc. Based on analysis of 101,957 FDA adverse event reports, METHYLPHENIDATE HYDROCHLORIDE has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for METHYLPHENIDATE HYDROCHLORIDE include DRUG INEFFECTIVE, FATIGUE, HEADACHE, NAUSEA, OFF LABEL USE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHYLPHENIDATE HYDROCHLORIDE.
Methylphenidate Hydrochloride has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 101,957 adverse event reports for this medication, which is primarily manufactured by Sandoz Inc.
The most commonly reported adverse events include Drug Ineffective, Fatigue, Headache. Of classified reports, 60.2% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Frequent reports of serious adverse events, including suicidal ideation and death.
Significant number of drug interactions and misuse reports. Common side effects include fatigue, headache, and nausea. Safety signals include increased aggression and cardiovascular issues. Reports of weight changes and sleep disturbances are also common.
Patients taking Methylphenidate Hydrochloride should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Methylphenidate Hydrochloride can interact with various drugs, including antidepressants and antipsychotics, and misuse is a known risk. Consumers should be aware of these interactions and follow prescribed dosages. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Methylphenidate Hydrochloride received a safety concern score of 65/100 (elevated concern). This is based on a 60.2% serious event ratio across 57,096 classified reports. The score accounts for 101,957 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 26,045, Male: 24,774, Unknown: 590. The most frequently reported age groups are age 9 (1,136 reports), age 10 (1,056 reports), age 14 (1,011 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 57,096 classified reports for METHYLPHENIDATE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Methylphenidate Hydrochloride can interact with various drugs, including antidepressants and antipsychotics, and misuse is a known risk. Consumers should be aware of these interactions and follow prescribed dosages.
If you are taking Methylphenidate Hydrochloride, here are important things to know. The most commonly reported side effects include drug ineffective, fatigue, headache, nausea, off label use. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Follow prescribed dosages and do not alter the medication without consulting a healthcare provider. Report any serious adverse events to the FDA's MedWatch program immediately. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors Methylphenidate Hydrochloride due to its serious adverse event profile. Healthcare providers should regularly assess patients for potential risks and benefits.
The FDA has received approximately 101,957 adverse event reports associated with Methylphenidate Hydrochloride. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Methylphenidate Hydrochloride include Drug Ineffective, Fatigue, Headache, Nausea, Off Label Use. By volume, the top reported reactions are: Drug Ineffective (6,068 reports), Fatigue (3,100 reports), Headache (2,897 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Methylphenidate Hydrochloride.
Out of 57,096 classified reports, 34,370 (60.2%) were classified as serious and 22,726 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Methylphenidate Hydrochloride break down by patient sex as follows: Female: 26,045, Male: 24,774, Unknown: 590. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Methylphenidate Hydrochloride adverse events are: age 9: 1,136 reports, age 10: 1,056 reports, age 14: 1,011 reports, age 8: 983 reports, age 11: 972 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Methylphenidate Hydrochloride adverse event reports is Sandoz Inc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Methylphenidate Hydrochloride include: Anxiety, Depression, Insomnia, Somnolence, Dizziness. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Methylphenidate Hydrochloride to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Methylphenidate Hydrochloride has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Frequent reports of serious adverse events, including suicidal ideation and death.
Key safety signals identified in Methylphenidate Hydrochloride's adverse event data include: Suicidal ideation and death reports are concerning.. Drug interactions and misuse are frequent.. Aggression and cardiovascular issues are key safety signals.. Weight changes and sleep disturbances are common.. Overdose and intentional misuse reports are significant.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Methylphenidate Hydrochloride can interact with various drugs, including antidepressants and antipsychotics, and misuse is a known risk. Consumers should be aware of these interactions and follow prescribed dosages. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Methylphenidate Hydrochloride.
Follow prescribed dosages and do not alter the medication without consulting a healthcare provider. Report any serious adverse events to the FDA's MedWatch program immediately.
Methylphenidate Hydrochloride has 101,957 adverse event reports on file with the FDA. Significant number of drug interactions and misuse reports. The volume of reports for Methylphenidate Hydrochloride reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors Methylphenidate Hydrochloride due to its serious adverse event profile. Healthcare providers should regularly assess patients for potential risks and benefits. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Sandoz Inc and compare their safety profiles:
The following drugs share commonly reported adverse reactions with METHYLPHENIDATE HYDROCHLORIDE:
Drugs related to METHYLPHENIDATE HYDROCHLORIDE based on therapeutic use, drug class, or shared indications: